Project Aura: Home Trial of a Home-based Monitoring Service

Sponsor
Entia Ltd (Industry)
Overall Status
Completed
CT.gov ID
NCT04137315
Collaborator
(none)
10
1
11.5
0.9

Study Details

Study Description

Brief Summary

This is a data collection study to compare diagnostic methods of a prototype of a home monitoring device against laboratory testing in the hospital.

Condition or Disease Intervention/Treatment Phase
  • Device: Blood measurement

Detailed Description

The device/monitoring system being developed measures the haemoglobin and haematocrit levels in blood from a single drop of blood. By measuring these blood parameters, participants are able to monitor their haemoglobin level at home.

The use of the device will take place in the participant's home to simulate what the investigators believe will be the ideal location for people who would prefer to self-manage their condition.

This study is a data collection study to evaluate the performance of the prototype.

Study Design

Study Type:
Observational
Actual Enrollment :
10 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Project Aura: Data Collection for a Home Monitoring Solution for Patients With Anaemia to Evaluate Delivery of Treatment
Actual Study Start Date :
Feb 14, 2020
Actual Primary Completion Date :
Jan 29, 2021
Actual Study Completion Date :
Jan 29, 2021

Outcome Measures

Primary Outcome Measures

  1. Quantitative capture of measurement system [6 months]

    Data collection for evaluation of measurement system

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥ 18 years of age.

  • Adequate english to participate in training sessions and use the analyser.

  • Patients of the study site who are currently undergoing treatment for anaemia of CKD with ESAs.

  • Patients who are not pregnant.

  • Patients who do not have a bleeding disorder.

  • Patients willing to perform self-tests 2-3 times a week.

  • Patients capable of providing informed consent before attending training.

  • Patients or patients with a carer capable of fine manipulation of the device and its consumables.

  • Patients or patients with a carer who own a smartphone which can download the app related to this study.

  • Patients or patients with carers who do not have eyesight limitations to be able to read the instructions on the screen of the prototype device.

  • Patients who are not expected to have to start dialysis treatment during the course of this study.

Exclusion Criteria:
  • Does not have adequate English to participate in training or use the analyser without an interpreter.

  • Patients of the study site who are not currently undergoing anaemia treatment with ESAs.

  • Patients of the study site not willing to perform self-tests 2-3 times a week.

  • Patients of the study site not capable of providing consent or have a suitable, legally acceptable representative present to provide consent before the trial.

  • Patients who are pregnant.

  • Patients with a bleeding disorder.

  • Patients or their nominated carers who are not capable of fine manipulation of the device and its consumables.

  • Neither patients or their nominated carers do not own a smartphone which can install the app related to this study.

  • Patients or their nominated carers with eyesight limitations to not be able to read the instructions on the screen of the prototype device.

  • Patients who are expected to start dialysis treatment during the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hull University Teaching Hospitals NHS Trust Hull United Kingdom HU3 2JZ

Sponsors and Collaborators

  • Entia Ltd

Investigators

  • Principal Investigator: Sunil Bhandari, FHEA, Hull University Teaching Hospitals NHS Trust

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Entia Ltd
ClinicalTrials.gov Identifier:
NCT04137315
Other Study ID Numbers:
  • IRAS: 272300
First Posted:
Oct 24, 2019
Last Update Posted:
Feb 9, 2021
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 9, 2021